Aura BiosciencesAURA
AURA
About: Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its lead candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
Employees: 89
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
217% more call options, than puts
Call options by funds: $1.09M | Put options by funds: $343K
175% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 4
20% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 25
9% more funds holding
Funds holding: 74 [Q2] → 81 (+7) [Q3]
6% more capital invested
Capital invested by funds: $310M [Q2] → $329M (+$19.4M) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]
8.4% less ownership
Funds ownership: 82.71% [Q2] → 74.31% (-8.4%) [Q3]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$22
167%
upside
Avg. target
$23
179%
upside
High target
$24
192%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Edward White 24% 1-year accuracy 33 / 140 met price target | 167%upside $22 | Buy Reiterated | 14 Nov 2024 |
Scotiabank George Farmer 20% 1-year accuracy 4 / 20 met price target | 179%upside $23 | Sector Outperform Maintained | 18 Oct 2024 |
BTIG Robert Hazlett 0% 1-year accuracy 0 / 3 met price target | 192%upside $24 | Buy Maintained | 18 Oct 2024 |
Financial journalist opinion
Neutral
GlobeNewsWire
3 weeks ago
Muscle Invasive Bladder Cancer Drug Pipeline Market Research 2024 Featuring Aura Biosciences, Janssen Research & Development, Asieris Pharmaceuticals, and RemeGen
This report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Muscle Invasive Bladder cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. This report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Muscle Invasive Bladder cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Positive
Seeking Alpha
2 months ago
Aura Biosciences: 2 Positive Bel-Sar Data Releases Brings Shareholder Value
The positive end of phase 2 study data was achieved using bel-sar for the treatment of patients with intermediate lesions and small choroidal melanoma. The global uveal melanoma treatment market is expected to reach $2.4 billion by 2033. Positive data was reported from the phase 1 study, using bel-sar for the treatment of patients with non-muscle invasive bladder cancer.
Positive
Benzinga
2 months ago
Aura Biosciences' Bladder Cancer Candidate Demonstrates Tumor Shrinkage In Patients With High-Grade Disease
On Thursday, Aura Biosciences, Inc. AURA revealed early data from an ongoing Phase 1 trial of bel-sar (AU-011) in patients with non-muscle-invasive bladder cancer (NMIBC).
Neutral
GlobeNewsWire
2 months ago
Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial
Clinical Complete Responses Observed in 4 out of 5 Patients in Subset of Patients with Low Grade Disease; Evidence of Bladder Urothelial Field Effect in Non-Target Tumors
Positive
Benzinga
2 months ago
3 Small-Cap Stocks Ready to Deliver Significant Growth
Small-cap stocks faced a challenging environment for the last several years as inflation and high interest rates dampened lending opportunities. These companies—which are often in the early stages of development and lack stability—rely heavily on debt to fuel their growth.
Neutral
MarketBeat
2 months ago
3 Small-Cap Stocks Ready to Deliver Significant Growth
Small-cap stocks faced a challenging environment for the last several years as inflation and high interest rates dampened lending opportunities. These companies—which are often in the early stages of development and lack stability—rely heavily on debt to fuel their growth.
Positive
Seeking Alpha
3 months ago
Sept. 13-20 Undercovered Stock Picks: Aura Biosciences, APA Corporation, iTeos, CuriosityStream +
The 'Undercovered' Dozen series highlights 12 undercovered stocks to provide another source for investment ideas and to encourage community discussion. Qurate Retail's losses are mainly due to non-cash markdowns, making it a potential buy despite declining revenue and net income losses, according to Bashar Issa. RLJ Lodging Trust offers a 7.5% yield on their preferred stock, and Aristofanis Papadatos sees this as attractive for income-oriented investors as interest rates are expected to decline.
Positive
Seeking Alpha
3 months ago
Aura Biosciences: Highly Derisked Late-Stage Eye Cancer Company
Aura Biosciences' lead asset, bel-sar, shows promising Phase 2 results for choroidal melanoma, with 80% tumor control and 90% vision preservation. Bel-sar's SPA designation by the FDA and its excellent safety profile position it favorably against current treatments like radiotherapy. Aura's financials are solid with a $499.53mn market cap and $187mn cash, providing a runway for its Phase 3 trial and additional studies.
Positive
Zacks Investment Research
3 months ago
Aura Stock Up as Lead Drug Shows Superior Efficacy in Eye Cancer Study
AURA stock up as lead candidate shows tumor control and visual acuity preservation abilities in eye cancer patients over 12 months of treatment.
Positive
Benzinga
3 months ago
Aura Biosciences Touts Promising Data From Eye Cancer Candidate
Thursday, Aura Biosciences, Inc. AURA revealed Phase 2 end-of-study results evaluating bel-sar (AU-011) for the first-line treatment of early-stage choroidal melanoma (CM), a vision and ocular cancer.
Charts implemented using Lightweight Charts™